Physician profile
Everardo Cobos
NPI 1194713354
$1,751.63
in general payments reported to CMS, 2019-2025
30 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $132 · 2021: $379 · 2022: $488 · 2023: $291 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $413 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $413.45 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $337.35 | 2019-2023 | Opdivo |
| Pfizer INC. | $150.05 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $144.83 | 2022-2023 | Lifevest |
| Astellas Pharma US INC | $138.08 | 2019-2022 | |
| Global Blood Therapeutics, INC. | $134.44 | 2020-2022 | |
| Genentech USA, INC. | $96.62 | 2023 | |
| Neurocrine Biosciences, INC. | $84.57 | 2025 | |
| Genzyme Corporation | $70.74 | 2021-2023 | |
| Gilead Sciences, INC. | $59.66 | 2022-2023 | Trodelvy |
| Carl Zeiss Meditec USA, INC. | $58.74 | 2025 | Intrabeam 600 |
| Morphosys, US INC. | $41.99 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $41.42 | 2020-2022 | |
| Janssen Biotech, INC. | $36.19 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $35.23 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.99 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $26.82 | 2022 | |
| Karyopharm Therapeutics INC. | $25.74 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $22.91 | 2022 | |
| Celgene Corporation | $22.90 | 2021 | |
| Adc Therapeutics America, INC. | $21.47 | 2022 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Incyte Corporation | $20.96 | 2022 | |
| Abbvie INC. | $18.60 | 2023 | Avycaz |
| Beigene USA, INC. | $17.58 | 2020 | |
| Janssen Scientific Affairs, LLC | $17.51 | 2021 | |
| Epizyme, INC. | $16.23 | 2022 | |
| Allergan, INC. | $16.07 | 2019 | |
| Merck Sharp & Dohme LLC | $15.23 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.42 | 2020 | |
| Blueprint Medicines Corporation | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Everardo Cobos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.